One of the latest companies to hit the public market is Caris Life Sciences (CAI). Pricing its IPO at $21 per share, Caris ...

在肿瘤医学领域，精准诊断的重要性不言而喻。但你知道吗？随着科技的发展，癌症的诊断和治疗正迎来一场革命！近日，Caris Life ...

Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, raised $494 million ...

Caris Life Sciences的股票一经上市，便引发了市场的强烈反应，开盘后股价飙升至近40%，最终以28美元收盘，涨幅达到33%。这场IPO的成功不仅是对Caris自身实力的认可，也标志着医疗科技领域的蓬勃发展。

The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public ...

Caris Life Sciences Inc., a health care company that uses technology to help diagnose and treat cancer, raised $494 million ...

The cancer diagnostics and treatment company priced shares above their earlier target range and might signal a renewed ...

The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.

David Dean Halbert, Caris Life Sciences chairman, founder and CEO, joins 'Squawk Box' to discuss the company's IPO debut, how ...

智通财经APP获悉，医疗科技公司Caris Life ...

Cancer-testing company raises $494 million in initial public offering.

Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the ...